BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
15.03.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160, SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Medison Pharma Ltd. a ... Seite 1